Search

Displaying results 2691 - 2700 of 4300 in total
  1. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    In 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].

  2. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]

  3. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing.

  4. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection.

  5. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. … Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

  6. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    Reliably studying the effects of Cannabis is complicated by the large variety of available strains and by the numerous other compounds that Cannabis contains such as terpenes, flavonoids, phenols, amino … While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified

  7. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.

  8. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    [L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions.

  9. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  10. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.